Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

May 07 2019

• By Mandy Jackson

Titled book Amyotrophic Lateral Sclerosis along with medical equipment, conceptual image - Image — Cytokinetics may move reldesemtiv into Phase III in ALS in 2020. • Source: Shutterstock

Related Content

With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup

Nov 21 2017

Radicava US Approval Boost To Mitsubishi As Sales Decline

May 08 2017

Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab

May 06 2017

Biohaven Readies Glutamate Modulator BHV-0223 For Phase III In Anxiety

Aug 17 2018

Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

Apr 19 2019

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

Oct 05 2018

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS

Sep 07 2018

Related Companies

Cytokinetics, Inc.

Astellas Pharma, Inc.

Mitsubishi Tanabe Pharma Corporation

University of Arizona

ADVANZ PHARMA Corp. Limited

Italfarmaco S.p.A.

Biohaven Pharmaceutical Holding Company Ltd.

Aquestive Therapeutics, Inc.

Additional Topics

Clinical Trials Rare Diseases Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window